Identification of candidate diagnostic biomarkers and gene networks for moderate stages of Alzheimer's disease in fusiform gyrus exhibiting neurofibrillary tangles
Restricted accessResearch articleFirst published online 2026
Identification of candidate diagnostic biomarkers and gene networks for moderate stages of Alzheimer's disease in fusiform gyrus exhibiting neurofibrillary tangles
Alzheimer's disease (AD) is a neurodegenerative disorder whose incidence grows with age and its development is gradual. However, if detected earlier there is much hope to prevent further exacerbation. In this study, NGS transcriptomics data from cases and controls with Braak scores of III-IV were investigated that all possessed neurofibrillary tangles (NFTs) in their fusiform gyrus.
Objective
The aim of this study was to discover the underlying mechanisms at gene level which could explain cognitive impairment by considering the presence of NFTs in both groups.
Methods
Differentially expressed genes (DEGs) were determined and ROC AUC were evaluated by leave-one-out cross-validation method on the diagnostic DEGs to detect candidate gene biomarkers. WGCNA was employed to identify co-expression modules with their trait association. Finally, in silico hybridization of lncRNAs from potential biomarkers with important AD-related microRNAs was carried out.
Results
Highly ranked potential diagnostic gene biomarkers revealed assessed AUC ranges of 80–90% in which RASGRF2-AS1 demonstrated the highest value. WGCNA demonstrated upregulated genes in favor of dephosphorylation of tau, proper proteostasis and vascular health in resilient controls whereas dysfunctional proteostasis, chronic protein misfolding, heightened cellular stress and tetrahydrobiopterin deficiency were attributed to cognitive impairment in AD patients. In silico analyses predicted some lncRNAs with a high possibility of acting as sponge for AD-related microRNAs.
Conclusions
This study discovered potential diagnostic gene biomarkers and transcriptional signatures that could explain the mechanisms of cognitive decline by considering the existence of NFTs, which could provide further insight for diagnosis and treatment of the disease.
KrishnamurthyHKJayaramanVKrishnaK, et al.An overview of the genes and biomarkers in Alzheimer's disease. Ageing Res Rev2025; 104: 102599.
2.
MetaxasAKempfSJ. Neurofibrillary tangles in Alzheimer's disease: elucidation of the molecular mechanism by immunohistochemistry and tau protein phospho-proteomics. Neural Regen Res2016; 11: 1579–1581.
SnowdonDAKemperSJMortimerJA, et al.Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. Findings from the Nun Study. JAMA1996; 275: 528–532.
5.
HaroutunianVPurohitDPPerlDP, et al.Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. Arch Neurol1999; 56: 713–718.
6.
BennettDASchneiderJAArvanitakisZ, et al.Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology2006; 66: 1837–1844.
7.
BokdeALLopez-BayoPMeindlT, et al.Functional connectivity of the fusiform gyrus during a face-matching task in subjects with mild cognitive impairment. Brain2006; 129: 1113–1124.
8.
TennantVRHarrisonTMAdamsJN, et al.Fusiform gyrus phospho-tau is associated with failure of proper name retrieval in aging. Ann Neurol2021; 90: 988–993.
9.
BancherCBrunnerCLassmannH, et al.Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease. Brain Res1989; 477: 90–99.
10.
RenZChuCPangY, et al.A group of long non-coding RNAs in blood acts as a specific biomarker of Alzheimer's disease. Mol Neurobiol2023; 60: 566–575.
11.
ZhangYZhaoYAoX, et al.The role of non-coding RNAs in Alzheimer's disease: from regulated mechanism to therapeutic targets and diagnostic biomarkers. Front Aging Neurosci2021; 13: 654978.
12.
WuXXiaPYangL, et al.The roles of long non-coding RNAs in Alzheimer's disease diagnosis, treatment, and their involvement in Alzheimer's disease immune responses. Noncoding RNA Res2024; 9: 659–666.
13.
FriedmanBASrinivasanKAyalonG, et al.Diverse brain myeloid expression profiles reveal distinct microglial activation states and aspects of Alzheimer's disease not evident in mouse models. Cell Rep2018; 22: 832–847.
14.
NieuwenhuisTOYangSYVermaRX, et al.Consistent RNA sequencing contamination in GTEx and other data sets. Nat Commun2020; 11: 1933.
15.
UhlénMFagerbergLHallströmBM, et al.Proteomics. Tissue-based map of the human proteome. Science2015; 347: 1260419.
16.
LorenzRBernhartSHHöner Zu SiederdissenC, et al.ViennaRNA Package 2.0. Algorithms Mol Biol2011; 6: 26.
17.
KrügerJRehmsmeierM. RNAhybrid: microRNA target prediction easy, fast and flexible. Nucleic Acids Res2006; 34: W451–W454.
18.
KeenanABTorreDLachmannA, et al.ChEA3: transcription factor enrichment analysis by orthogonal omics integration. Nucleic Acids Res2019; 47: W212–w224.
19.
ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature2012; 489: 57–74.
20.
NeefDWJaegerAMThieleDJ. Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases. Nat Rev Drug Discov2011; 10: 930–944.
21.
GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science2020; 369: 1318–1330.
22.
KornienkoAEGuenzlPMBarlowDP, et al.Gene regulation by the act of long non-coding RNA transcription. BMC Biol2013; 11: 59.
23.
VillegasVEZaphiropoulosPG. Neighboring gene regulation by antisense long non-coding RNAs. Int J Mol Sci2015; 16: 3251–3266.
24.
KirschLChechikG. On expression patterns and developmental origin of human brain regions. PLoS Comput Biol2016; 12: e1005064.
25.
DarcyMJTroucheSSXJ, et al.Ras-GRF2 mediates long-term potentiation, survival, and response to an enriched environment of newborn neurons in the hippocampus. Hippocampus2014; 24: 1317–1329.
26.
StaceyDBilbaoAMaroteauxM, et al.RASGRF2 Regulates alcohol-induced reinforcement by influencing mesolimbic dopamine neuron activity and dopamine release. Proc Natl Acad Sci U S A2012; 109: 21128–21133.
27.
SchwechterBRosenmundCToliasKF. RasGRF2 Rac-GEF activity couples NMDA receptor calcium flux to enhanced synaptic transmission. Proc Natl Acad Sci U S A2013; 110: 14462–14467.
28.
YangLJWuWJiangWR, et al.Upregulation of RasGRF1 ameliorates spatial cognitive dysfunction in mice after chronic cerebral hypoperfusion. Aging (Albany NY)2023; 15: 2999–3020.
29.
KesavapanySAminNZhengYL, et al.P35/cyclin-dependent kinase 5 phosphorylation of ras guanine nucleotide releasing factor 2 (RasGRF2) mediates Rac-dependent Extracellular Signal-regulated kinase 1/2 activity, altering RasGRF2 and microtubule-associated protein 1b distribution in neurons. J Neurosci2004; 24: 4421–4431.
30.
SundaramJRChanESPooreCP, et al.Cdk5/p25-induced cytosolic PLA2-mediated lysophosphatidylcholine production regulates neuroinflammation and triggers neurodegeneration. J Neurosci2012; 32: 1020–1034.
31.
LiuYYangHLvG, et al.Integration analysis of cis- and trans-regulatory long non-coding RNAs associated with immune-related pathways in non-small cell lung cancer. Biochem Biophys Rep2024; 40: 101832.
32.
WooJALiuTFangCC, et al.β-Arrestin2 oligomers impair the clearance of pathological tau and increase tau aggregates. Proc Natl Acad Sci U S A2020; 117: 5006–5015.
33.
ThathiahAHorréKSnellinxA, et al.β-arrestin 2 regulates Aβ generation and γ-secretase activity in Alzheimer's disease. Nat Med2013; 19: 43–49.
34.
PengQLiuYYuL, et al.Deletion of Arrb2 down-regulates autophagy in the mouse hippocampus via Akt-mTOR pathway activation. Neuroscience2023; 519: 120–130.
35.
BogaertsVEngelborghsSKumar-SinghS, et al.A novel locus for dementia with Lewy bodies: a clinically and genetically heterogeneous disorder. Brain2007; 130: 2277–2291.
36.
Florentinus-MefailoskiABowdenPScheltensP, et al.The plasma peptides of Alzheimer's disease. Clin Proteomics2021; 18: 17.
37.
BraithwaiteSPStockJBLombrosoPJ, et al.Protein phosphatases and Alzheimer's disease. Prog Mol Biol Transl Sci2012; 106: 343–379.
38.
SunLLiuSYZhouXW, et al.Inhibition of protein phosphatase 2A- and protein phosphatase 1-induced tau hyperphosphorylation and impairment of spatial memory retention in rats. Neuroscience2003; 118: 1175–1182.
39.
XiaoYWeiLSuJ, et al.A tau dephosphorylation-targeting chimeraselectively recruits protein phosphatase-1 to ameliorate Alzheimer's disease and tauopathies. Cell Chem Biol2024; 31: 1787–1799.e1786.
40.
GongCXSinghTJGrundke-IqbalI, et al.Phosphoprotein phosphatase activities in Alzheimer disease brain. J Neurochem1993; 61: 921–927.
41.
LemaireSFerreiraMClaesZ, et al.PPP1R2 Stimulates protein phosphatase-1 through stabilisation of dynamic subunit interactions. Nat Commun2024; 15: 9822.
42.
RincicMBrecevicLLiehrT, et al.Customized chromosomal microarrays for neurodevelopmental disorders. Genes (Basel)2025; 16: 868.
43.
RibeiroFCCozachencoDHeimfarthL, et al.Synaptic proteasome is inhibited in Alzheimer's disease models and associates with memory impairment in mice. Commun Biol2023; 6: 1127.
44.
WingoAPLiuYGerasimovES, et al.Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer's disease pathogenesis. Nat Genet2021; 53: 143–146.
45.
BellenguezCKüçükaliFJansenIE, et al.New insights into the genetic etiology of Alzheimer's disease and related dementias. Nat Genet2022; 54: 412–436.
46.
CullellNGallego-FábregaCCárcel-MárquezJ, et al.ICA1L Is associated with small vessel disease: a proteome-wide association study in small vessel stroke and intracerebral haemorrhage. Int J Mol Sci2022; 23: 3161.
47.
NationDASweeneyMDMontagneA, et al.Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med2019; 25: 270–276.
48.
ChaarDLLiZShangL, et al.Multi-ancestry transcriptome-wide association studies of cognitive function, white matter hyperintensity, and Alzheimer’s disease. Int J Mol Sci2025; 26: 2443.
49.
DeshimaruMKinoshita-KawadaMKubotaK, et al.DCTN1 Binds to TDP-43 and regulates TDP-43 aggregation. Int J Mol Sci2021; 22: 3985.
50.
ZhangCHuangZHuangX, et al.PLK2 Disrupts autophagic flux to promote SNCA/α-synuclein pathology. Autophagy2025; 21: 1623–1643.
51.
FilomenaEPicardiETulloA, et al.Identification of deregulated lncRNAs in Alzheimer's disease: an integrated gene co-expression network analysis of hippocampus and fusiform gyrus RNA-seq datasets. Front Aging Neurosci2024; 16: 1437278.
52.
HetzCSaxenaS. ER Stress and the unfolded protein response in neurodegeneration. Nat Rev Neurol2017; 13: 477–491.
53.
BertolottiAZhangYHendershotLM, et al.Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nat Cell Biol2000; 2: 326–332.
54.
HoozemansJJvan HaastertESNijholtDA, et al.The unfolded protein response is activated in pretangle neurons in Alzheimer's disease hippocampus. Am J Pathol2009; 174: 1241–1251.
55.
HoshinoTNakayaTArakiW, et al.Endoplasmic reticulum chaperones inhibit the production of amyloid-beta peptides. Biochem J2007; 402: 581–589.
56.
HsuWCWangHKLeeLC, et al.Promoter polymorphisms modulating HSPA5 expression may increase susceptibility to Taiwanese Alzheimer's disease. J Neural Transm (Vienna)2008; 115: 1537–1543.
57.
PaziMBBelanDVKomarovaEY, et al.Intranasal administration of GRP78 protein (HSPA5) confers neuroprotection in a lactacystin-induced rat model of Parkinson's disease. Int J Mol Sci2024; 25: 3951.
GorbatyukMSShabashviliAChenW, et al.Glucose regulated protein 78 diminishes α-synuclein neurotoxicity in a rat model of Parkinson disease. Mol Ther2012; 20: 1327–1337.
60.
MayerMPBukauB. Hsp70 chaperones: cellular functions and molecular mechanism. Cell Mol Life Sci2005; 62: 670–684.
61.
JinwalUKAkouryEAbisambraJF, et al.Imbalance of Hsp70 family variants fosters tau accumulation. FASEB J2013; 27: 1450–1459.
62.
YoungZTRauchJNAssimonVA, et al.Stabilizing the Hsp70-tau complex promotes turnover in models of tauopathy. Cell Chem Biol2016; 23: 992–1001.
63.
WangZZhangHChengQ. PDIA4: the basic characteristics, functions and its potential connection with cancer. Biomed Pharmacother2020; 122: 109688.
64.
MedinasDBRozasPHetzC. Critical roles of protein disulfide isomerases in balancing proteostasis in the nervous system. J Biol Chem2022; 298: 102087.
65.
PerriERThomasCJParakhS, et al.The unfolded protein response and the role of protein disulfide isomerase in neurodegeneration. Front Cell Dev Biol2015; 3: 80.
66.
HonjoYItoHHoribeT, et al.Protein disulfide isomerase-immunopositive inclusions in patients with Alzheimer disease. Brain Res2010; 1349: 90–96.
67.
NakamuraTLiptonSA. Redox modulation by S-nitrosylation contributes to protein misfolding, mitochondrial dynamics, and neuronal synaptic damage in neurodegenerative diseases. Cell Death Differ2011; 18: 1478–1486.
68.
TownsendDMManevichYHeL, et al.Nitrosative stress-induced s-glutathionylation of protein disulfide isomerase leads to activation of the unfolded protein response. Cancer Res2009; 69: 7626–7634.
69.
IrwinRFaustOPetrovicI, et al.Hsp40s play complementary roles in the prevention of tau amyloid formation. Elife2021; 10: e69601.
70.
FerrariRRFantiniVGarofaloM, et al.A map of transcriptomic signatures of different brain areas in Alzheimer's disease. Int J Mol Sci2024; 25: 11117.
71.
FontaineSNZhengDSabbaghJJ, et al.Dnaj/Hsc70 chaperone complexes control the extracellular release of neurodegenerative-associated proteins. EMBO J2016; 35: 1537–1549.
72.
RupawalaHShahKDaviesC, et al.Cysteine string protein alpha accumulates with early pre-synaptic dysfunction in Alzheimer's disease. Brain Commun2022; 4: fcac192.
73.
BhattacharyaKPicardD. The Hsp70–Hsp90 go-between Hop/Stip1/Sti1 is a proteostatic switch and may be a drug target in cancer and neurodegeneration. Cell Mol Life Sci2021; 78: 7257–7273.
74.
BatkoJAntoszKMiśkówW, et al.Chaperones-a new class of potential therapeutic targets in Alzheimer's disease. Int J Mol Sci2024; 25: 3401.
75.
KwokJO'SheaMHumeDA, et al.Jmjd6, a JmjC dioxygenase with many interaction partners and pleiotropic functions. Front Genet2017; 8: 32.
76.
MerchantJPZhuKHenrionMYR, et al.Predictive network analysis identifies JMJD6 and other potential key drivers in Alzheimer's disease. Commun Biol2023; 6: 503.
77.
AzizAALeemingRJBlairJA. Tetrahydrobiopterin metabolism in senile dementia of Alzheimer type. J Neurol Neurosurg Psychiatry1983; 46: 410–413.
78.
FoxtonRHLandJMHealesSJ. Tetrahydrobiopterin availability in Parkinson's and Alzheimer's disease; potential pathogenic mechanisms. Neurochem Res2007; 32: 751–756.
79.
FanetHTournissacMLeclercM, et al.Tetrahydrobiopterin improves recognition memory in the triple-transgenic mouse model of Alzheimer's disease, without altering amyloid-β and tau pathologies. J Alzheimers Dis2021; 79: 709–727.
80.
TobinJECuiJWilkJB, et al.Sepiapterin reductase expression is increased in Parkinson's disease brain tissue. Brain Res2007; 1139: 42–47.
81.
ZhangMGanzABRohdeS, et al.Resilience and resistance to the accumulation of amyloid plaques and neurofibrillary tangles in centenarians: an age-continuous perspective. Alzheimers Dement2023; 19: 2831–2841.
82.
DeaneCASBrownIR. Intracellular targeting of heat shock proteins in differentiated human neuronal cells following proteotoxic stress. J Alzheimers Dis2018; 66: 1295–1308.
83.
WangYJDiXJZhangPP, et al.Hsp47 promotes biogenesis of multi-subunit neuroreceptors in the endoplasmic reticulum. Elife2024; 13: e84798.
84.
EnglerMJMimuraJYamazakiS, et al.JDP2 Is directly regulated by ATF4 and modulates TRAIL sensitivity by suppressing the ATF4-DR5 axis. FEBS Open Bio2020; 10: 2771–2779.
85.
ScheperWHoozemansJJ. The unfolded protein response in neurodegenerative diseases: a neuropathological perspective. Acta Neuropathol2015; 130: 315–331.
86.
RadfordHMorenoJAVerityN, et al.PERK Inhibition prevents tau-mediated neurodegeneration in a mouse model of frontotemporal dementia. Acta Neuropathol2015; 130: 633–642.
87.
NijholtDAvan HaastertESRozemullerAJ, et al.The unfolded protein response is associated with early tau pathology in the hippocampus of tauopathies. J Pathol2012; 226: 693–702.
88.
NystuenKLMcNameeSMAkulaM, et al.Alzheimer's disease: models and molecular mechanisms informing disease and treatments. Bioengineering (Basel)2024; 11: 45.
89.
BehlTKyadaARoopashreeR, et al.Epigenetic biomarkers in Alzheimer's disease: diagnostic and prognostic relevance. Ageing Res Rev2024; 102: 102556.
90.
NguyenHDVuGHKimW-K. Identification of biomarkers and molecular mechanisms implicated in genetic variations underlying Alzheimer's disease pathogenesis. Asp Mol Med2024; 3: 100045.
91.
YamazakiYZhaoNCaulfieldTR, et al.Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol2019; 15: 501–518.
92.
ChenHHEteleebAWangC, et al.Circular RNA detection identifies circPSEN1 alterations in brain specific to autosomal dominant Alzheimer's disease. Acta Neuropathol Commun2022; 10: 29.
93.
AdlakhaYKSainiN. Brain microRNAs and insights into biological functions and therapeutic potential of brain enriched miRNA-128. Mol Cancer2014; 13: 33.
94.
AbsalonSKochanekDMRaghavanV, et al.MiR-26b, upregulated in Alzheimer's disease, activates cell cycle entry, tau-phosphorylation, and apoptosis in postmitotic neurons. J Neurosci2013; 33: 14645–14659.
95.
KimY-JKimSHParkY, et al.miR-16-5p is upregulated by amyloid β deposition in Alzheimer's disease models and induces neuronal cell apoptosis through direct targeting and suppression of BCL-2. Exp Gerontol2020; 136: 110954.
96.
MaQZhaoHTaoZ, et al.MicroRNA-181c exacerbates brain injury in acute ischemic stroke. Aging Dis2016; 7: 705–714.
97.
ShioyaMObayashiSTabunokiH, et al.Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3. Neuropathol Appl Neurobiol2010; 36: 320–330.
98.
WangWXHuangQHuY, et al.Patterns of microRNA expression in normal and early Alzheimer's disease human temporal cortex: white matter versus gray matter. Acta Neuropathol2011; 121: 193–205.
99.
LiangCZhuHXuY, et al.MicroRNA-153 negatively regulates the expression of amyloid precursor protein and amyloid precursor-like protein 2. Brain Res2012; 1455: 103–113.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
